The Toxicity Profile of Concurrent Nivolumab and Ipilimumab

October 4, 2014
Harriet Kluger, MD

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.

Clinical Pearls

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.

  • Additive toxicity was found between these agents.
  • The grade 3/4 adverse event rate was greater than 50%.
  • Most adverse events were reversible with immunosuppressants.

<<<

View more from the 2014 ESMO Congress